The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients with newly diagnosed glioblastoma.
S. Phuphanich
Research Funding - ImmunoCellular Therapeutics
C. J. Wheeler
No relevant relationships to disclose
J. Rudnick
No relevant relationships to disclose
M. Mazer
No relevant relationships to disclose
M. Nuno
No relevant relationships to disclose
X. Fan
No relevant relationships to disclose
J. Bender
Employment or Leadership Position - ImmunoCellular Therapeutics
Stock Ownership - ImmunoCellular Therapeutics
E. S. Hawkins
Employment or Leadership Position - ImmunoCellular Therapeutics
Consultant or Advisory Role - ImmunoCellular Therapeutics
Stock Ownership - ImmunoCellular Therapeutics
K. L. Black
Employment or Leadership Position - ImmunoCellular Therapeutics
Stock Ownership - ImmunoCellular Therapeutics
Research Funding - ImmunoCellular Therapeutics
J. Yu
Employment or Leadership Position - ImmunoCellular Therapeutics
Stock Ownership - ImmunoCellular Therapeutics
Research Funding - ImmunoCellular Therapeutics